(Corrects dateline to August 26) (Reuters) -Makers of weight-loss drugs are expected to rake in more than $150 billion in ...

Novo Nordisk A/S (NYSE:NVO) is one of the stocks on Jim Cramer’s and analysts’ radar. On August 22, DBS Bank analyst Nico ...

A competitor reported a successful late-stage clinical trial of a drug that could be very competitive with Wegovy.

The future of obesity therapeutics is being written now – be a part of it! Visit the full agenda and speakers here: ...

Novo Nordisk said on Monday it is offering its diabetes drug Ozempic for $499 per month to eligible cash-paying type 2 ...

Novo Nordisk (NVO) stock was down on Tuesday, despite a lack of news from the pharmaceutical company. Instead, investors can ...

The 36-mg dose brought the greatest weight loss, 10.5%, while the 12-mg dose group shed 7.8% of their body weight on average.

The bankruptcy filing allowed WeightWatchers to cut its debt by $1bn without entirely wiping out existing shareholders: they ...

“This afternoon, LLY reported data from P3 ATTAIN-2 trial, evaluating oral GLP-1RA orforglipron in over 1,600 adults with ...

The results of the ATTAIN-2 study, which involved people with obesity or overweight with type 2 diabetes, showed that the ...

As the political winds shift on a whim and public distrust of the pharma industry reaches fever pitch over drug pricing, ...

Second Nature will maintain existing September prices across all doses of Mounjaro for its members, absorbing the cost ...